Medtronic's Cardiovascular Boom Offsets Margin Pressure

Medtronic stock rose 5.21% Wednesday after reporting Q4 earnings that beat expectations with revenue of $9.81 billion (up 9.9% YoY) and adjusted EPS of $1.55. Strong growth in Cardiovascular (up 13.8%) and Diabetes (up 15.0%) segments drove performance, though operating margins contracted 230 basis points due to MiniMed Blackstone payment and tariffs. The company raised its dividend to 72 cents quarterly and provided FY2027 guidance of $5.90-$6.00 EPS, slightly below analyst expectations.